{"dataset":{"name":"GLP-1 Pipeline Tracker — Investigational Anti-Obesity Drugs (2026)","description":"The anti-obesity programs the register tracks toward readout, one row per trial, giving sponsor and mechanism, phase and status, the NCT ID, the indication under study, and the date primary completion is expected. Most rows are Phase 3; a few are earlier dose-finding work, one is an approved molecule's indication expansion, and a couple are China-only programs with no announced US filing. Every row was checked against its ClinicalTrials.gov record, with peer-reviewed publications read at the source rather than cited from memory.","url":"https://glpwatchdog.org/glp1-pipeline","creator":"GLP Watchdog","license":"https://creativecommons.org/licenses/by/4.0/","licenseName":"CC BY 4.0","dateModified":"2026-09-11","temporalCoverage":"2026-09-11/..","rowCount":17,"csv":"https://glpwatchdog.org/api/datasets/glp1-pipeline.csv","catalog":"https://glpwatchdog.org/api/datasets/index.json","fields":[{"name":"drug_name","description":"The molecule's international nonproprietary name, with the brand name where one has been assigned."},{"name":"generic_alias","description":"Development code or alternate name the sponsor uses (e.g., LY3437943 for retatrutide)."},{"name":"sponsor","description":"Company running the trial program."},{"name":"mechanism","description":"How the molecule acts (e.g., GLP-1 / GIP / glucagon triple agonist)."},{"name":"phase","description":"Trial phase as ClinicalTrials.gov states it. Observed values are Phase 3, Phase 3 expansion, Phase 2b and Phase 2, so match on the string rather than assuming a two-value field."},{"name":"NCT_id","description":"Registry identifier of the pivotal trial on ClinicalTrials.gov."},{"name":"primary_completion_date","description":"Primary completion date as ClinicalTrials.gov lists it: month and year, or a full date where we could confirm one."},{"name":"indication","description":"What the trial is treating. Values include obesity and chronic weight management, T2D + obesity, MASH, OSA, and CVD outcomes."},{"name":"status","description":"Status at last verification. Observed values are 'Completed', 'Active, not recruiting', 'Approved (expansion)' and 'Unknown (registry not updated)', the last where ClinicalTrials.gov itself lists the record as unknown."},{"name":"trial_name","description":"Program name the sponsor gave the trial (e.g., TRIUMPH-1, MARITIME-2, REDEFINE-3)."},{"name":"clinicaltrials_url","description":"Permanent URL of the trial record on ClinicalTrials.gov."}]},"summary":{"asOf":"2026-09-11","rowCount":17,"license":"https://creativecommons.org/licenses/by/4.0/","licenseName":"CC BY 4.0","citation":"GLP Watchdog, \"GLP-1 Pipeline Tracker — Investigational Anti-Obesity Drugs (2026)\", data as of 2026-09-11. https://glpwatchdog.org/glp1-pipeline","about":"GLP-1 Pipeline Tracker — Investigational Anti-Obesity Drugs (2026): 17 rows. Data as of 2026-09-11."},"rows":[{"drug_name":"Retatrutide","generic_alias":"LY3437943","sponsor":"Eli Lilly","mechanism":"GIP / GLP-1 / glucagon triple agonist","phase":"Phase 3","NCT_id":"NCT05929066","primary_completion_date":"April 6, 2026","indication":"Obesity (without T2D)","status":"Completed","trial_name":"TRIUMPH-1","clinicaltrials_url":"https://clinicaltrials.gov/study/NCT05929066"},{"drug_name":"Retatrutide","generic_alias":"LY3437943","sponsor":"Eli Lilly","mechanism":"GIP / GLP-1 / glucagon triple agonist","phase":"Phase 3","NCT_id":"NCT05929079","primary_completion_date":"June 16, 2026","indication":"T2D + obesity","status":"Completed","trial_name":"TRIUMPH-2","clinicaltrials_url":"https://clinicaltrials.gov/study/NCT05929079"},{"drug_name":"Retatrutide","generic_alias":"LY3437943","sponsor":"Eli Lilly","mechanism":"GIP / GLP-1 / glucagon triple agonist","phase":"Phase 3","NCT_id":"NCT05882045","primary_completion_date":"April 16, 2026","indication":"Severe obesity (BMI ≥35) + established CVD","status":"Completed","trial_name":"TRIUMPH-3","clinicaltrials_url":"https://clinicaltrials.gov/study/NCT05882045"},{"drug_name":"Retatrutide","generic_alias":"LY3437943","sponsor":"Eli Lilly","mechanism":"GIP / GLP-1 / glucagon triple agonist","phase":"Phase 3","NCT_id":"NCT05931367","primary_completion_date":"November 14, 2025","indication":"Obesity + knee osteoarthritis","status":"Completed","trial_name":"TRIUMPH-4","clinicaltrials_url":"https://clinicaltrials.gov/study/NCT05931367"},{"drug_name":"Retatrutide","generic_alias":"LY3437943","sponsor":"Eli Lilly","mechanism":"GIP / GLP-1 / glucagon triple agonist","phase":"Phase 3","NCT_id":"NCT06383390","primary_completion_date":"February 2029","indication":"BMI ≥27 + ASCVD or CKD (CV and kidney outcomes)","status":"Active, not recruiting","trial_name":"TRIUMPH-Outcomes","clinicaltrials_url":"https://clinicaltrials.gov/study/NCT06383390"},{"drug_name":"Maridebart cafraglutide","generic_alias":"MariTide","sponsor":"Amgen","mechanism":"GIPR antagonist + GLP-1 agonist mAb-peptide (monthly Q4W)","phase":"Phase 3","NCT_id":"NCT06858839","primary_completion_date":"January 2027","indication":"Obesity (without T2D)","status":"Active, not recruiting","trial_name":"MARITIME-1","clinicaltrials_url":"https://clinicaltrials.gov/study/NCT06858839"},{"drug_name":"Maridebart cafraglutide","generic_alias":"MariTide","sponsor":"Amgen","mechanism":"GIPR antagonist + GLP-1 agonist mAb-peptide (monthly Q4W)","phase":"Phase 3","NCT_id":"NCT06858878","primary_completion_date":"January 2027","indication":"T2D + obesity","status":"Active, not recruiting","trial_name":"MARITIME-2","clinicaltrials_url":"https://clinicaltrials.gov/study/NCT06858878"},{"drug_name":"CagriSema","generic_alias":"cagrilintide 2.4 mg + semaglutide 2.4 mg","sponsor":"Novo Nordisk","mechanism":"Amylin analog + GLP-1 agonist fixed-dose combo","phase":"Phase 3","NCT_id":"NCT05567796","primary_completion_date":"October 2024","indication":"Obesity (without T2D)","status":"Active, not recruiting","trial_name":"REDEFINE-1","clinicaltrials_url":"https://clinicaltrials.gov/study/NCT05567796"},{"drug_name":"CagriSema","generic_alias":"cagrilintide 2.4 mg + semaglutide 2.4 mg","sponsor":"Novo Nordisk","mechanism":"Amylin analog + GLP-1 agonist fixed-dose combo","phase":"Phase 3","NCT_id":"NCT05394519","primary_completion_date":"January 2025","indication":"T2D + obesity","status":"Completed","trial_name":"REDEFINE-2","clinicaltrials_url":"https://clinicaltrials.gov/study/NCT05394519"},{"drug_name":"CagriSema","generic_alias":"cagrilintide 2.4 mg + semaglutide 2.4 mg","sponsor":"Novo Nordisk","mechanism":"Amylin analog + GLP-1 agonist fixed-dose combo","phase":"Phase 3","NCT_id":"NCT05669755","primary_completion_date":"September 2027","indication":"Established CVD (event-driven CVOT)","status":"Active, not recruiting","trial_name":"REDEFINE-3","clinicaltrials_url":"https://clinicaltrials.gov/study/NCT05669755"},{"drug_name":"Survodutide","generic_alias":"BI 456906","sponsor":"Boehringer Ingelheim / Zealand Pharma","mechanism":"GLP-1 / glucagon dual agonist","phase":"Phase 3","NCT_id":"NCT06066515","primary_completion_date":"December 2025","indication":"Obesity (without T2D)","status":"Completed","trial_name":"SYNCHRONIZE-1","clinicaltrials_url":"https://clinicaltrials.gov/study/NCT06066515"},{"drug_name":"Orforglipron / Foundayo","generic_alias":"Oral non-peptide GLP-1 RA (FDA-approved Apr 1, 2026)","sponsor":"Eli Lilly","mechanism":"Non-peptide oral GLP-1 receptor agonist","phase":"Phase 3 expansion","NCT_id":"NCT06649045","primary_completion_date":"November 2026","indication":"OSA + obesity (one expansion; T2D separately submitted to FDA)","status":"Approved (expansion)","trial_name":"ATTAIN-OSA","clinicaltrials_url":"https://clinicaltrials.gov/study/NCT06649045"},{"drug_name":"Ecnoglutide","generic_alias":"XW003","sponsor":"Sciwind Biosciences","mechanism":"Weekly GLP-1 receptor agonist","phase":"Phase 3","NCT_id":"NCT05813795","primary_completion_date":"June 2024","indication":"Chronic weight management (China; no US filing announced)","status":"Completed","trial_name":"SLIMMER","clinicaltrials_url":"https://clinicaltrials.gov/study/NCT05813795"},{"drug_name":"Pemvidutide","generic_alias":"ALT-801","sponsor":"Altimmune","mechanism":"GLP-1 / glucagon dual agonist","phase":"Phase 2b","NCT_id":"NCT05989711","primary_completion_date":"November 25, 2025","indication":"MASH (FDA Breakthrough Therapy + Fast Track; Phase 3 PERFORMA started Jul 30, 2026)","status":"Completed","trial_name":"IMPACT","clinicaltrials_url":"https://clinicaltrials.gov/study/NCT05989711"},{"drug_name":"Bimagrumab + Semaglutide","generic_alias":"BYM338 + semaglutide (via Versanis)","sponsor":"Eli Lilly (Versanis acquisition)","mechanism":"Activin type II receptor blocker + GLP-1 agonist","phase":"Phase 2","NCT_id":"NCT05616013","primary_completion_date":"May 2024","indication":"Obesity — fat mass reduction","status":"Completed","trial_name":"BELIEVE","clinicaltrials_url":"https://clinicaltrials.gov/study/NCT05616013"},{"drug_name":"Mazdutide","generic_alias":"IBI362","sponsor":"Innovent / Eli Lilly (China license)","mechanism":"GCG / GLP-1 dual agonist","phase":"Phase 3","NCT_id":"NCT06164873","primary_completion_date":"June 2025 (stale registry estimate; JAMA: trial ran to Nov 2025)","indication":"Chronic weight management (China; no US filing announced)","status":"Unknown (registry not updated)","trial_name":"GLORY-2","clinicaltrials_url":"https://clinicaltrials.gov/study/NCT06164873"},{"drug_name":"Petrelintide","generic_alias":"ZP8396","sponsor":"Zealand Pharma / Roche","mechanism":"Long-acting amylin analog","phase":"Phase 2","NCT_id":"NCT06662539","primary_completion_date":"September 2025","indication":"Obesity (dose-finding; Phase 3 planned H2 2026)","status":"Completed","trial_name":"ZUPREME-1","clinicaltrials_url":"https://clinicaltrials.gov/study/NCT06662539"}]}